🕵️ Neurogene Inc. ($NGNE)
SEC insider & ownership activity, last 12 months · CIK 1404644 · every row links its SEC filing
Over the last 12 months insiders sold $1.1M with no open-market buying against it. Cvijic Christine Mikail sold $900K through a 10b5-1 trading plan in 12 lots (Feb–Jul). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 4 sellers, $1.1M (17 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Cvijic Christine Mikail | 0 | – | 12 | $900K | Jul 7, 2026 |
| Stuart Cobb | 0 | – | 3 | $141K | Mar 13, 2026 |
| McMinn Rachel | 0 | – | 1 | $74K | Mar 26, 2026 |
| Jordan Julie | 0 | – | 1 | $18K | Mar 26, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| RTW Investments, LP | 10.0% | 13G | Feb 14, 2025 | filing ↗ | |
| Roderick WONG, M.D. | 10.0% | 13G | Feb 14, 2025 | filing ↗ | |
| Redmile Group, LLC | 9.9% | 13G | Feb 17, 2026 | filing ↗ | |
| Jeremy C. Green | 9.9% | 13G | Feb 17, 2026 | filing ↗ | |
| ECOR1 Capital, LLC | 9.9% | 13G | Nov 14, 2025 | filing ↗ | |
| Oleg Nodelman | 9.9% | 13G | Nov 14, 2025 | filing ↗ | |
| Casdin Capital, LLC | 8.7% | 13G | Feb 14, 2025 | filing ↗ | |
| Eli Casdin | 8.7% | 13G | Feb 14, 2025 | filing ↗ | |
| ECOR1 Capital Fund Qualified, L.P. | 8.6% | 13G | Nov 14, 2025 | filing ↗ | |
| Casdin Partners Master Fund, L.P. | 7.2% | 13G | Feb 14, 2025 | filing ↗ | |
| Casdin Partners GP, LLC | 7.2% | 13G | Feb 14, 2025 | filing ↗ | |
| Baker BROS. Advisors LP | 7.0% | 13G | Aug 14, 2025 | filing ↗ | |
| Baker BROS. Advisors (GP) LLC | 7.0% | 13G | Aug 14, 2025 | filing ↗ | |
| Julian C. Baker | 7.0% | 13G | Aug 14, 2025 | filing ↗ | |
| Felix J. Baker | 7.0% | 13G | Aug 14, 2025 | filing ↗ | |
| Blackrock, Inc. | 6.8% | 13G | Apr 23, 2025 | filing ↗ | |
| Trails EDGE Capital Partners, LP | 5.1% | 13G | Dec 15, 2025 | filing ↗ | |
| Trails EDGE Biotechnology Master Fund, LP | 5.1% | 13G | Dec 15, 2025 | filing ↗ | |
| Ortav Yehudai | 5.1% | 13G | Dec 15, 2025 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Christine Cvijic | $417K | May 6, 2026 | filing ↗ |
| Stuart Cobb | $152K | Mar 13, 2026 | filing ↗ |
| Christine Cvijic | $189K | Feb 27, 2026 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Material agreement (1.01) | Jun 30, 2026 | filing ↗ |
| Other events (8.01) | Jun 30, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 30, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 29, 2026 | filing ↗ |
| Other events (8.01) | Jun 29, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 29, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 8, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 3, 2026 | filing ↗ |
| Earnings (2.02) | May 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 12, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 20, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 20, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 20, 2026 | filing ↗ |
| Earnings (2.02) | Mar 24, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 24, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Feb 26, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 26, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 12, 2026 | filing ↗ |
| Earnings (2.02) | Nov 13, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 13, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 12, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 12, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 6, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 6, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Oct 9, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Oct 9, 2025 | filing ↗ |
| Earnings (2.02) | Aug 11, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 11, 2025 | filing ↗ |